Literature Review and an Italian Hospital Experience about Post-Natal CMV Infection Acquired by Breast-Feeding in Very Low and/or Extremely Low Birth Weight Infants

• Published in: Nutrients Vol. 13; no. 2; p. 660
• Main Authors: Garofoli, Francesca, Civardi, Elisa, Zanette, Simona, Angelini, Micol, Perotti, Gianfranco, Zecca, Marco, Lombardi, Giuseppina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.02.2021; MDPI
• Subjects: Adult; Antiviral agents; Breast Feeding - adverse effects; breastfeeding; Cytomegalovirus; Cytomegalovirus infections; Cytomegalovirus Infections - epidemiology; Cytomegalovirus Infections - transmission; Female; Health aspects; Hospitals; Humans; Infant, Newborn; Infant, Very Low Birth Weight; Infants; Infectious Disease Transmission, Vertical - statistics & numerical data; Italy - epidemiology; Milk, Human - virology; post-natally acquired cytomegalovirus; Pregnancy; Pregnancy Complications, Infectious - virology; preterm infants; Review; Italy; post-natally acquired cytomegalovirus; preterm infants; breastfeeding
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu13020660

Breastfeeding is recommended for all neonates due to a known variety of beneficial effects, but infants can be infected by cell-associated bacteria and viruses from breast milk, such as cytomegalovirus (CMV). The majority of CMV-seropositive breastfeeding women have a viral, self-restricted reactivation, can shed the virus in the milk for about 12 weeks after delivery, and can transmit the infection to their offspring. Post-natal CMV-infected term infants are mainly asymptomatic, while very low birth weight (VLBW, <1500 g) and extremely low birth weight (ELBW, <1000 g) infants may present with severe disease, short-term sequelae ranging from abnormalities in laboratory indexes to sepsis-like syndrome, and long-term sequelae such as developmental problems. Thus, the use of thermally treated maternal milk for VLBW/ELBW infants may be indicated to prevent/reduce the risk of CMV transmission. Different techniques, with varying efficacy in eradicating CMV and maintaining the activity of biological compounds in milk are available: long/short pasteurization, freeze-thawing, the use of microwaves, and ultraviolet-C irradiation. In our NICU, the use of maternal raw milk is always strongly recommended for term/preterm infants, but to reduce risk of CMV transmission, freeze-thawing mother's own milk is used in neonates with GA ≤ 30 weeks or/and weight ≤ 1000 g, usually regardless of serological maternal condition, as CMV screening is not routinely offered to pregnant women and the milk of seroimmune mothers is not evaluated for CMV reactivation, as its rate is similar to seroprevalence. Over the last 4 years, we had 10 VLBW/ELBW newborns in our NICU with late-onset sepsis and negative cultures. In these cases, the research of CMV DNA in neonatal urine or saliva, for the diagnosis of post-natal symptomatic infection (once congenital transmission has been excluded) may be useful and not invasive. The take-home message we would like to share is that acquired CMV infection should be considered in VLBW/ELBW infants breastfed by seropositive mothers and presenting severe symptoms-particularly sepsis with negative cultures. This could allow pediatricians to make better-quality diagnoses, perform supportive therapy, provide antiviral treatment if needed, or establish a "pre-emptive" therapy for these high-risk neonates.